Want to see TSE:OTC full AI Analyst Report?
Top Page
Ocumetics Technology Corp
(OTC)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.46
▲(7.21% Upside)
Action:Reiterated
Date:08/30/26
The score is driven primarily by very weak financial performance—no revenue, rising losses, ongoing cash burn, and a strained balance sheet with negative equity and high leverage relative to assets. Technical signals are neutral-to-soft (below longer-term moving averages, negative MACD), and valuation provides limited support due to negative earnings and no dividend data.
Positive Factors
Focused ophthalmic product development
The company is concentrated on a clearly defined ophthalmic implant rather than a broad set of unrelated activities. If development and regulatory preparation progress successfully, the Bionic Lens could support a differentiated commercialization pathway in vision correction over the next several quarters.
Negative Factors
No commercialization yet
Persistent zero revenue indicates the product has not yet reached meaningful commercialization, leaving the company without an operating revenue base to fund research, regulatory work, or expansion. Until sales begin, progress remains dependent on external capital and successful product development.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused ophthalmic product development
The company is concentrated on a clearly defined ophthalmic implant rather than a broad set of unrelated activities. If development and regulatory preparation progress successfully, the Bionic Lens could support a differentiated commercialization pathway in vision correction over the next several quarters.
Read all positive factors
Ocumetics Technology Corp (OTC) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$31.47M
Dividend YieldN/A
Average Volume (3M)19.66K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue GrowthN/A
EPS Growth-90.61%
CountryCA
Employees5
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.06
Shares Outstanding65,564,430
10 Day Avg. Volume29,383
30 Day Avg. Volume19,655
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ocumetics Technology Corp Business Overview & Revenue Model
Company Description
Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within th...
Ocumetics Technology Corp Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -156.19K | -149.37K | -134.30K | -117.62K | -102.21K | -96.18K |
| EBITDA | -4.33M | -3.87M | -2.29M | -3.50M | -2.09M | -3.42M |
| Net Income | -7.57M | -5.37M | -3.02M | -3.64M | -2.22M | -598.19K |
Balance Sheet | ||||||
| Total Assets | 748.53K | 1.90M | 2.32M | 1.04M | 1.37M | 825.25K |
| Cash, Cash Equivalents and Short-Term Investments | 88.74K | 464.04K | 1.57M | 235.83K | 602.09K | 83.90K |
| Total Debt | 4.31M | 5.30M | 3.95M | 321.64K | 292.34K | 0.00 |
| Total Liabilities | 5.14M | 5.85M | 4.26M | 945.33K | 536.45K | 1.10M |
| Stockholders Equity | -4.39M | -3.94M | -1.94M | 91.10K | 837.40K | -270.50K |
Cash Flow | ||||||
| Free Cash Flow | -2.70M | -3.49M | -2.51M | -2.19M | -1.69M | -213.63K |
| Operating Cash Flow | -2.66M | -3.37M | -2.43M | -2.05M | -1.62M | -89.13K |
| Investing Cash Flow | -103.94K | 1.25M | -1.46M | -142.17K | -66.82K | -214.92K |
| Financing Cash Flow | 2.44M | 2.38M | 3.85M | 1.82M | 444.35K | 387.11K |
Ocumetics Technology Corp Technical Analysis
Positive
0.43
Price Trends
0.46
Positive
0.50
Negative
0.53
Negative
Market Momentum
>-0.01
Negative
62.16
Neutral
91.41
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OTC, the sentiment is Positive. The current price of 0.43 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.46, and below the 200-day MA of 0.53, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 62.16 is Neutral, neither overbought nor oversold. The STOCH value of 91.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:OTC.
Ocumetics Technology Corp Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | C$91.14M | 20.98 | 15.04% | 6.94% | 4.11% | 88.39% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | C$46.03M | -2.38 | -303.05% | ― | 35.27% | 58.34% | |
48 Neutral | C$12.49M | -7.51 | -34.32% | ― | -5.42% | -5.37% | |
43 Neutral | C$18.32M | -4.87 | 78.25% | ― | 89.06% | 37.62% | |
42 Neutral | C$31.47M | -8.14 | 175.10% | ― | ― | -90.61% |
* General Sector Average
TSE:OTC
Ocumetics Technology Corp
0.48
-0.54
-52.94%
TSE:ASG
Aurora Spine
0.16
-0.09
-36.00%
TSE:COV
Covalon Technologies
3.30
1.15
53.49%
TSE:PINK
Perimeter Medical Imaging AI
0.30
0.09
42.86%
TSE:VPT
VentriPoint Diagnostics
0.10
>-0.01
-9.52%
TSE:CNVI
Conavi Medical
0.17
-0.29
-63.33%
Ocumetics Technology Corp Corporate Events
Business Operations and StrategyProduct-Related Announcements
Ocumetics Readies Next-Gen Intraocular Lens for Second Human Trials
Positive
Aug 31, 2026
Ocumetics Technology Corp. has completed manufacturing of its next-generation solid state accommodating intraocular lenses, clearing the way for Group Two first-in-human clinical surgeries in Mexico City. The lenses, produced in Germany and set to...
Business Operations and StrategyPrivate Placements and Financing
Ocumetics Completes Final Tranche of $3.1 Million Private Placement to Advance Lens Trials
Positive
Aug 24, 2026
Ocumetics Technology Corp. has completed the third and final tranche of its previously announced unit private placement. In this last tranche, the company issued 405,000 units at $0.40 per unit, each comprising one common share and one warrant, br...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.